港股医药股走弱，港股创新药相关ETF跌超2%

Group 1 - Hong Kong pharmaceutical stocks weakened, with Innovent Biologics down over 4%, China Biologic Products down over 3%, and other companies like CanSino Biologics, CSPC Pharmaceutical Group, and Kelun-Biotech down over 2% [1] - The Hong Kong innovative drug-related ETFs also fell by over 2% due to market influences [1] Group 2 - Various Hong Kong innovative drug ETFs experienced declines, with the Southbound T+0 ETF down 3.52%, the Hang Seng Innovative Drug ETF down 2.92%, and others showing similar downward trends [2] - Analysts suggest that after a decade of transformation, China's innovative drug industry is entering a harvest period, with a steady increase in the number of domestically approved innovative drugs and significant overseas transactions [2]